Open AccessAnticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake
Author(s) -
Т. В. Вавилова
Publication year - 2019
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.n951
Subject(s) - rivaroxaban , apixaban , pharmacodynamics , coagulation cascade , pharmacology , anticoagulant , medicine , thrombin , coagulation , drug , dabigatran , pharmacokinetics , discovery and development of direct thrombin inhibitors , warfarin , intensive care medicine , platelet , atrial fibrillation
The thematic review presents modern solutions using oral anticoagulants with a focus on direct coagulation factor X inhibitors. It contains information about the pharmacodynamics and pharmacokinetics of apixaban and rivaroxaban against the background of different drug intake regimens - twice and once per day. There are shown studies of concentration dynamics and the corresponding functional response, measured using the integral method - the thrombin generation test, which is widely used in scientific research to describe hemostatic processes based on an objective quantitative assessment of the thrombin formation – a key coagulation cascade serine protease. The logical relationship between the pharmacodynamics of anticoagulant action and the clinical presentation of the effectiveness and safety of drugs is traced. The review provides links to actual literature and current clinical guidelines.